EGFR and non-small cell lung carcinoma: Therefore, treatment strategies involving 4G EGFR-TKIs would be either (a) as a second-line treatment after front-line osimertinib failure or (b) as a front-line therapy for EGFR-mutated NSCLC (Figure 1).